Non-nucleoside reverse transcriptase inhibitors

A method of treating an HIV infected patient comprising administering to the patient a pharmaceutical composition comprising a compound in a dose effective to reduce viral propagation wherein the compound has a structure according to Formula (A) or Formula (B)

• wherein R1 is optionally substituted lower alkyl, halogen, or CF3,
• R2 is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted quinoline, or optionally substituted isoquinoline;
• and
• R3, R4, and R5 are independently hydrogen, halogen, optionally substituted alkyl, S-alkyl, CF3, heterocycle, NR′R″, S(O)2R′, or C(O)R′, and wherein R′ and R″ are independently NH2, NHAlkyl, NHAcyl, NAlkylAcyl, N(Alkyl)2, O-alkyl, acyl, aryl, alkyl, heterocycle, or R′ and R″ form a ring.

A compound having a structure according to Formula (VI)

• HET-W—C(R1)(R2)—C(Y)—N(R4R5) (VI)
• wherein HET comprises a disubstituted 1,2,4-triazole or a disubstituted imidazole, wherein at least one substituent of HET is a substituted aryl, and wherein the substituted aryl is covalently bound to a nitrogen of HET;
• W is O, S, S(O), S(O)2, NH, NR1 or CH2;
• R1 and R2 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, halogen, OH, SH, NH2, N3, O-alkyl, or CH2OH;
• Y is O, S, or NR3, wherein R3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, or hydroxy, O-alkyl, or CH2OH;
• R4 is hydrogen, lower alkyl, lower alkenyl, or lower alkynyl;
• and
• R5 is an ortho-substituted phenyl, which is optionally further substituted.

A compound having a structure according to Formula (A) or (B)

• wherein R1 is optionally substituted lower alkyl, or halogen,
• R2 is selected from the group consisting of a monosubstituted phenyl, a disubstituted phenyl, a trisubstituted phenyl, a monosubstituted naphthyl, a disubstituted naphthyl, a trisubstituted naphthyl, a monosubstituted quinoline, a disubstituted quinoline, a trisubstituted quinoline, a monosubstituted isoquinoline, a disubstituted isoquinoline, and a trisubstituted isoquinoline;
• and
• R3, R4, and R5 are independently hydrogen, halogen, optionally substituted alkyl, S-alkyl, CF3, heterocycle, NR′R″, S(O)2R′, or C(O)R′, and wherein R′ and R″ are independently NH2, NHAlkyl, NHAcyl, NAlkylAcyl, N(Alkyl)2, O-alkyl, acyl, aryl, alkyl, heterocycle, or R′ and R″ form a ring.